Hypothesis

Gut-derived indole-3-propionic acid (IPA) enhances the brain’s nightly ‘autopsy’ by activating the aryl hydrocarbon receptor (AhR) on astrocytes, which drives apolipoprotein‑dependent translocation and stabilization of aquaporin‑4 (AQP4) to perivascular endfeet. This augments interstitial fluid expansion during NREM slow‑wave sleep, thereby increasing glymphatic clearance of soluble τ‑protein and amyloid‑β. In states of low IPA (e.g., antibiotic depletion, dysbiosis, or aging), AhR signaling wanes, AQP4 becomes mislocalized, glymphatic flux declines, and the nocturnal triage fails to retain synaptic architectures that support cognitive resilience, accelerating brain age.

Mechanistic Rationale

1. AhR as a sensor of microbial indoles – IPA is a high‑affinity ligand for AhR, a transcription factor known to regulate astrocytic reactivity and water‑channel expression (https://doi.org/10.1038/s41467-020-15119-w).
2. AH‑R‑dependent AQP4 polarization – AhR activation upregulates α‑syntrophin and promotes AQP4 clustering at astrocytic endfeet, a prerequisite for efficient glymphatic influx (https://pmc.ncbi.nlm.nih.gov/articles/PMC12202386/).
3. Link to slow‑wave activity – Enhanced perivascular CSF influx correlates with larger slow‑wave amplitude (0.70 A.U., d=0.86) (https://pmc.ncbi.nlm.nih.gov/articles/PMC12202386/). IPA‑mediated AQP4 stabilization should thus boost first‑cycle NREM flux, measurable as increased CSF‑to‑brain tracer transfer.
4. Consequences for proteostasis – Improved clearance lowers interstitial τ and Aβ, reducing the burden that drives epigenetic aging clocks (https://pmc.ncbi.nlm.nih.gov/articles/PMC7085452/).

Testable Predictions

• Human trial: Oral IPA supplementation (500 mg/day for 4 weeks) in middle‑aged adults will increase (a) fecal IPA concentrations, (b) EEG slow‑wave power (0.5–4 Hz) during NREM, and (c) glymphatic CSF‑influx rate measured by intrathecal gadolinium‑based MRI (https://academic.oup.com/braincomms/article/5/6/fcad343/7470760) compared with placebo.
• Mechanistic blockade: Co‑administration of an AhR antagonist (e.g., CH‑223191) will abolish the IPA‑induced increases in slow‑wave power and glymphatic flux, confirming AhR dependence.
• Animal validation: Germ‑free mice colonized with an IPA‑producing Clostridium sporogenes strain will show higher AQP4 perivascular localization, greater CSF‑influx (two‑photon tracer), and lower cortical p‑Tau181 after sleep deprivation than mono‑associated controls lacking the IPA pathway.
• Falsification: If IPA supplementation fails to alter either slow‑wave activity or glymphatic tracer clearance despite achieving physiological plasma IPA levels, the hypothesis is refuted.

Implications

Positioning IPA as a modulator of the brain’s nocturnal triage reframes sleep‑linked longevity from passive waste removal to an active, microbiome‑gated selection process. It offers a biomarker‑driven avenue (fecal IPA + EEG slow‑wave + MRI glymphatic index) to predict cognitive resilience and to intervene with precision prebiotics or IPA analogues before irreversible neurodegeneration takes hold.